InsiderTrades

Form 4 for VOR Vor Biopharma Inc.

Accepted 2026-08-26 18:28:56 ET · period of report 2026-08-24 · accession 0001231919-26-001102 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2026-08-26 18:28 2026-08-24 VOR RA CAPITAL MANAGEMENT, L.P. 10% M - OptEx $3.74 +1,500 1,500 New +$5,604
DI 2026-08-26 18:28 2026-08-24 VOR RA CAPITAL MANAGEMENT, L.P. 10% M - OptEx $0.00 -1,500 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-08-24 M A 1,500 $3.74 1,500 I See footnotes — — (F1) On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The exercise price and number of shares underlying the stock option give effect to the reverse stock split. (F1) On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The exercise price and number of shares underlying the stock option give effect to the reverse stock split. (F2) RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. (F3) This option was granted to Joshua Resnick pursuant to the Issuer's non-employee director compensation policy. Under Mr. Resnick's arrangement with the Adviser, Mr. Resnick held the option for the benefit of the Fund. Mr. Resnick is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
2 Derivative Stock Option (Right to Buy) 2026-08-24 M D 1,500 $0.00 0 I See Footnotes $3.74 · — to 2026-08-26 1,500 Common Stock (F1) On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The exercise price and number of shares underlying the stock option give effect to the reverse stock split. (F1) On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The exercise price and number of shares underlying the stock option give effect to the reverse stock split. (F5) Immediately exercisable. (F1) On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The exercise price and number of shares underlying the stock option give effect to the reverse stock split. (F2) RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. (F3) This option was granted to Joshua Resnick pursuant to the Issuer's non-employee director compensation policy. Under Mr. Resnick's arrangement with the Adviser, Mr. Resnick held the option for the benefit of the Fund. Mr. Resnick is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.